News
ARWR
47.15
-4.48%
-2.21
Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate
Benzinga · 3h ago
Arrowhead reports FY26 EPS ($5.11) vs ($3.51) last year
TipRanks · 3h ago
Arrowhead Pharmaceuticals GAAP EPS of -$5.11 misses by $1.51, revenue of $450.82M misses by $13.32M
Seeking Alpha · 3h ago
Press Release: Arrowhead Pharmaceuticals Reports -3-
Dow Jones · 3h ago
Press Release: Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
Dow Jones · 3h ago
Arrowhead Research: Fiscal Q4 Earnings Snapshot
Barchart · 9h ago
Here are the major earnings after the close Thursday
Seeking Alpha · 9h ago
How Investors May Respond To Arrowhead Pharmaceuticals (ARWR) Positive Heart Conference Data
Simply Wall St · 23h ago
Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test
Benzinga · 1d ago
Arrowhead's First Commercial Year Is Here, but Revenue May Not Show It
Barchart · 1d ago
Analysts Are Bullish on Top Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Kura Oncology (KURA)
TipRanks · 1d ago
Crispr Therapeutics: The Recent 40% Drop In Short Interest Indicates Deteriorating Bearish Sentiment
Seeking Alpha · 2d ago
PepGen Stock Spikes 132% on Rare-Disease Win. These Rivals Are Feeling The Pressure.
Barron‘s · 2d ago
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 2d ago
Piper Sandler Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks · 2d ago
Arrowhead Pharmaceuticals Becomes Oversold (ARWR)
NASDAQ · 3d ago
What Do Arrowhead Pharmaceuticals (ARWR) New AHA Trial Results Change?
Simply Wall St · 3d ago
Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today
Benzinga · 3d ago
Arrowhead Pharmaceuticals Down Over 18%, on Pace for Largest Percent Decrease Since November 2023 -- Data Talk
Dow Jones · 3d ago
Arrowhead falls -17.7%
TipRanks · 3d ago
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.